Pande Atul 4

What Happened Atul Pande, a director of Immunovant (IMVT), exercised options to acquire 1,500 common shares at a strike price of $8.43 (cost $12,645) on July 24, 2026, and the same day sold 1,500 shares in an open-market transaction at $39.80 each for proceeds of $59,700. The filing also records a derivative conversion/disposition of 1,500 shares at $0.00 (see footnotes for context). The exercise reflects option ownership being converted into shares; the immediate sale means the position was largely monetized that day (routinely done for liquidity or tax reasons).

Key Details

• Transaction date: 2026-07-24
• Exercise: 1,500 shares @ $8.43 = $12,645 (code M — option exercise)
• Sale: 1,500 shares @ $39.80 = $59,700 (open market sale, code S)
• Derivative conversion: 1,500 shares recorded @ $0.00 (code M)
• Footnotes: F1 — the sale occurred pursuant to a Rule 10b5-1 trading plan adopted Dec 26, 2025; F2 — reflects an award of fully vested stock options
• Shares owned after the transactions: not specified in this filing
• Filing timeliness: no late-filing indication in this report

Context

• Because the exercise and sale occurred the same day, this was effectively a same-day exercise-and-sell (often called a cashless exercise or sale to cover), which converts option value into cash rather than a long-term shareholding.
• The reported sale was executed under a pre-established 10b5-1 plan, which is commonly used by insiders to schedule trades in advance and avoid accusations of opportunistic timing.
• These transactions are factual disclosures of insider activity; they do not by themselves indicate company performance or management sentiment.